Cargando…
Peripheral endocannabinoid serum level in association with repetitive transcranial magnetic stimulation (rTMS) treatment in patients with major depressive disorder
Repetitive transcranial magnetic stimulation (rTMS) is an effective and well tolerable biological intervention in major depressive disorder (MDD) contributing to rapid symptom improvement. Molecular mechanisms underpinning the therapeutic effects of rTMS have still not been clarified. Recently publi...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8065048/ https://www.ncbi.nlm.nih.gov/pubmed/33893327 http://dx.doi.org/10.1038/s41598-021-87840-5 |
_version_ | 1783682260721991680 |
---|---|
author | Lazary, Judit Elemery, Monika Dome, Peter Kiss, Szilvia Gonda, Xenia Tombor, Laszlo Pogany, Laszlo Becskereki, Gergely Toth, Blanka Faludi, Gabor |
author_facet | Lazary, Judit Elemery, Monika Dome, Peter Kiss, Szilvia Gonda, Xenia Tombor, Laszlo Pogany, Laszlo Becskereki, Gergely Toth, Blanka Faludi, Gabor |
author_sort | Lazary, Judit |
collection | PubMed |
description | Repetitive transcranial magnetic stimulation (rTMS) is an effective and well tolerable biological intervention in major depressive disorder (MDD) contributing to rapid symptom improvement. Molecular mechanisms underpinning the therapeutic effects of rTMS have still not been clarified. Recently published animal data implicated relevant associations with changes in endocannabinoid (eCB) brain levels during rTMS treatment, human studies, however, have not been published. In our study we assessed the detailed phenotypic spectrum of MDD and serum 2-arachidnoylglycerol (2-AG) and anandamide (AEA) levels in 18 patients with treatment-resistant depression before, immediately following, and two weeks after completion of a 10-day rTMS treatment. We found significant associations between serum 2-AG level changes from pretreatment to 2 weeks after treatment and symptom reduction. The greater the increase of 2-AG levels, the greater the improvement of depressive (p = 0.031), anxious (p = 0.007) and anhedonia symptoms (p = 0.047). Here we report for the first time a significant association of human circulating eCB and antidepressant effect of rTMS. Our data may indicate that direct stimulation of targeted brain areas can rapidly alleviate depressive complaints via activation of the eCB system. |
format | Online Article Text |
id | pubmed-8065048 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-80650482021-04-27 Peripheral endocannabinoid serum level in association with repetitive transcranial magnetic stimulation (rTMS) treatment in patients with major depressive disorder Lazary, Judit Elemery, Monika Dome, Peter Kiss, Szilvia Gonda, Xenia Tombor, Laszlo Pogany, Laszlo Becskereki, Gergely Toth, Blanka Faludi, Gabor Sci Rep Article Repetitive transcranial magnetic stimulation (rTMS) is an effective and well tolerable biological intervention in major depressive disorder (MDD) contributing to rapid symptom improvement. Molecular mechanisms underpinning the therapeutic effects of rTMS have still not been clarified. Recently published animal data implicated relevant associations with changes in endocannabinoid (eCB) brain levels during rTMS treatment, human studies, however, have not been published. In our study we assessed the detailed phenotypic spectrum of MDD and serum 2-arachidnoylglycerol (2-AG) and anandamide (AEA) levels in 18 patients with treatment-resistant depression before, immediately following, and two weeks after completion of a 10-day rTMS treatment. We found significant associations between serum 2-AG level changes from pretreatment to 2 weeks after treatment and symptom reduction. The greater the increase of 2-AG levels, the greater the improvement of depressive (p = 0.031), anxious (p = 0.007) and anhedonia symptoms (p = 0.047). Here we report for the first time a significant association of human circulating eCB and antidepressant effect of rTMS. Our data may indicate that direct stimulation of targeted brain areas can rapidly alleviate depressive complaints via activation of the eCB system. Nature Publishing Group UK 2021-04-23 /pmc/articles/PMC8065048/ /pubmed/33893327 http://dx.doi.org/10.1038/s41598-021-87840-5 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Lazary, Judit Elemery, Monika Dome, Peter Kiss, Szilvia Gonda, Xenia Tombor, Laszlo Pogany, Laszlo Becskereki, Gergely Toth, Blanka Faludi, Gabor Peripheral endocannabinoid serum level in association with repetitive transcranial magnetic stimulation (rTMS) treatment in patients with major depressive disorder |
title | Peripheral endocannabinoid serum level in association with repetitive transcranial magnetic stimulation (rTMS) treatment in patients with major depressive disorder |
title_full | Peripheral endocannabinoid serum level in association with repetitive transcranial magnetic stimulation (rTMS) treatment in patients with major depressive disorder |
title_fullStr | Peripheral endocannabinoid serum level in association with repetitive transcranial magnetic stimulation (rTMS) treatment in patients with major depressive disorder |
title_full_unstemmed | Peripheral endocannabinoid serum level in association with repetitive transcranial magnetic stimulation (rTMS) treatment in patients with major depressive disorder |
title_short | Peripheral endocannabinoid serum level in association with repetitive transcranial magnetic stimulation (rTMS) treatment in patients with major depressive disorder |
title_sort | peripheral endocannabinoid serum level in association with repetitive transcranial magnetic stimulation (rtms) treatment in patients with major depressive disorder |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8065048/ https://www.ncbi.nlm.nih.gov/pubmed/33893327 http://dx.doi.org/10.1038/s41598-021-87840-5 |
work_keys_str_mv | AT lazaryjudit peripheralendocannabinoidserumlevelinassociationwithrepetitivetranscranialmagneticstimulationrtmstreatmentinpatientswithmajordepressivedisorder AT elemerymonika peripheralendocannabinoidserumlevelinassociationwithrepetitivetranscranialmagneticstimulationrtmstreatmentinpatientswithmajordepressivedisorder AT domepeter peripheralendocannabinoidserumlevelinassociationwithrepetitivetranscranialmagneticstimulationrtmstreatmentinpatientswithmajordepressivedisorder AT kissszilvia peripheralendocannabinoidserumlevelinassociationwithrepetitivetranscranialmagneticstimulationrtmstreatmentinpatientswithmajordepressivedisorder AT gondaxenia peripheralendocannabinoidserumlevelinassociationwithrepetitivetranscranialmagneticstimulationrtmstreatmentinpatientswithmajordepressivedisorder AT tomborlaszlo peripheralendocannabinoidserumlevelinassociationwithrepetitivetranscranialmagneticstimulationrtmstreatmentinpatientswithmajordepressivedisorder AT poganylaszlo peripheralendocannabinoidserumlevelinassociationwithrepetitivetranscranialmagneticstimulationrtmstreatmentinpatientswithmajordepressivedisorder AT becskerekigergely peripheralendocannabinoidserumlevelinassociationwithrepetitivetranscranialmagneticstimulationrtmstreatmentinpatientswithmajordepressivedisorder AT tothblanka peripheralendocannabinoidserumlevelinassociationwithrepetitivetranscranialmagneticstimulationrtmstreatmentinpatientswithmajordepressivedisorder AT faludigabor peripheralendocannabinoidserumlevelinassociationwithrepetitivetranscranialmagneticstimulationrtmstreatmentinpatientswithmajordepressivedisorder |